- Home
- CSTL vs INNV Comparison
CSTL vs INNV Comparison
Compare CSTL & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- INNV
- Stock Information
- Founded
- CSTL 2007
- INNV 2007
- Country
- CSTL United States
- INNV United States
- Employees
- CSTL N/A
- INNV N/A
- Industry
- CSTL Medical Specialities
- INNV Medical/Nursing Services
- Sector
- CSTL Health Care
- INNV Health Care
- Exchange
- CSTL Nasdaq
- INNV Nasdaq
- Market Cap
- CSTL 456.2M
- INNV 527.9M
- IPO Year
- CSTL 2019
- INNV 2021
- Fundamental
- Price
- CSTL $18.52
- INNV $3.89
- Analyst Decision
- CSTL Strong Buy
- INNV Sell
- Analyst Count
- CSTL 6
- INNV 2
- Target Price
- CSTL $37.67
- INNV $5.00
- AVG Volume (30 Days)
- CSTL 419.5K
- INNV 32.0K
- Earning Date
- CSTL 08-04-2025
- INNV 05-06-2025
- Dividend Yield
- CSTL N/A
- INNV N/A
- EPS Growth
- CSTL N/A
- INNV N/A
- EPS
- CSTL N/A
- INNV N/A
- Revenue
- CSTL $347,083,000.00
- INNV $831,683,000.00
- Revenue This Year
- CSTL N/A
- INNV $13.77
- Revenue Next Year
- CSTL $1.36
- INNV $10.12
- P/E Ratio
- CSTL N/A
- INNV N/A
- Revenue Growth
- CSTL 38.43
- INNV 12.19
- 52 Week Low
- CSTL $15.45
- INNV $2.60
- 52 Week High
- CSTL $35.84
- INNV $6.69
- Technical
- Relative Strength Index (RSI)
- CSTL 56.09
- INNV 54.58
- Support Level
- CSTL $17.89
- INNV $3.62
- Resistance Level
- CSTL $19.38
- INNV $4.03
- Average True Range (ATR)
- CSTL 0.82
- INNV 0.19
- MACD
- CSTL 0.26
- INNV -0.04
- Stochastic Oscillator
- CSTL 77.46
- INNV 57.38
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.